Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

MoonLake Immunotherapeutics (NASDAQ:MLTX) develops the tri-specific nanobody Sonelokimab (SLK), a chemical that targets and penetrates difficult-to-reach inflammatory regions.

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most ...

MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10. A successful year including the announcements of positive ...

ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a good speculative biotech play to look into.That's because it reported positive results from a phase 2 study using its drug sonelokimab for the ...

MoonLake Immunotherapeutics AG. New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...